South Africa launches breakthrough HIV prevention shot : NPR
South Africa has officially launched a biannual injectable HIV prevention drug, Lenacapavir, marking a significant development in the nation’s long-standing battle against the virus. The rollout, which began this past Friday, is currently being implemented across 360 health facilities in high-burden districts. As the ninth country in Africa to introduce the treatment, South Africa aims to leverage this “failproof” preventative injection to address its status as the nation with the highest number of HIV cases globally.
Did You Know? South Africa is currently managing about 8 million people living with HIV, and despite successful efforts to place a majority of the population on antiretroviral drugs, the country still records approximately 160,000 new infections every year.
A Shift in Prevention Strategy
The primary target for the new rollout includes adolescent girls and young women aged 15 to 24, a demographic experiencing roughly 1,000 new infections each week. While daily oral PrEP pills have been available, adherence has remained a persistent challenge. Experts believe the twice-yearly injection, administered into the stomach, could offer a more manageable solution for individuals struggling with daily medication regimens.
Expert Insight: The arrival of Lenacapavir represents a critical transition from daily medical maintenance to a semi-annual intervention. However, the successful integration of this technology into public health infrastructure hinges on overcoming immediate funding gaps and supply chain hurdles, which currently threaten to limit the reach of this potential breakthrough.
Financial and Logistical Challenges
Despite the optimism surrounding the drug, its implementation faces significant headwinds. The Trump administration’s decision to slash funding for the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) has negatively impacted HIV prevention infrastructure, community outreach, and youth services. These cuts, coupled with the high current cost of the drug—approximately $28,000 per person annually in the U.S.—have restricted the number of doses currently available.
Future Outlook
The landscape for HIV prevention in South Africa could shift significantly by 2027. A deal to produce generic versions of Lenacapavir is expected to lower the cost to approximately $40 per person per year, potentially allowing the South African government to scale up the program. Scientific modeling suggests that if one to two million HIV-negative people receive the injection by 2043, AIDS could cease to be a major public health problem in the country.
Frequently Asked Questions
What is Lenacapavir?
Lenacapavir is a form of Pre-exposure Prophylaxis (PrEP) that is injected into the stomach every six months to prevent high-risk individuals from contracting HIV.
Why is the current rollout limited?
Access is limited primarily by U.S. Funding cuts to PEPFAR, which have affected prevention infrastructure, and the current high cost of the drug, which is manufactured by the U.S. Pharmaceutical company Gilead.
When will more affordable versions be available?
Generic versions of the drug are expected to become available in 2027 at a projected cost of around $40 per person per year.
How do you believe advancements in long-acting injectable medications will reshape the future of public health initiatives in your community?